American Century Companies’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

American Century Companies’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-67,071	Closed	-$1.77M	–	2374
2021 Q4	$1.77M	Buy	67,071 +2,213	+3%	+$171K	﹤0.01%	1412
2021 Q3	$6.53M	Buy	64,858 +20	+0%	+$2.34K	﹤0.01%	958
2021 Q2	$9.18M	Buy	64,838 +31,185	+93%	+$3.52M	0.01%	841
2021 Q1	$3.35M	Sell	33,653 -712	-2%	-$83K	﹤0.01%	1038
2020 Q4	$4.25M	Buy	34,365 +49	+0.1%	+$6.44K	﹤0.01%	911
2020 Q3	$3.34M	Buy	34,316 +231	+0.7%	+$28.9K	﹤0.01%	859
2020 Q2	$5.32M	Buy	34,085 +8,558	+34%	+$1.3M	0.01%	767
2020 Q1	$3.69M	Sell	25,527 -5,564	-18%	-$1.07M	﹤0.01%	770
2019 Q4	$6.36M	Buy	31,091 +1,688	+6%	+$308K	0.01%	772
2019 Q3	$2.36M	Sell	29,403 -2,506	-8%	-$213K	﹤0.01%	946
2019 Q2	$3.01M	Sell	31,909 -87	-0.3%	-$7.51K	﹤0.01%	949
2019 Q1	$2.73M	Sell	31,996 -9,128	-22%	-$758K	﹤0.01%	946
2018 Q4	$2.31M	Buy	41,124 +11,000	+37%	+$672K	﹤0.01%	945
2018 Q3	$2.46M	Buy	+30,124	New	+$2.12M	﹤0.01%	999

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

American Century Companies's RETA Position: Q1 2022 in Review

American Century Companies sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2022, closing a stake of 67,071 shares — an estimated $1.77M sold.

American Century Companies first reported a position in RETA in Q3 2018 and held it in 14 quarters. The position peaked at $9.18M in Q2 2021. 149 funds tracked by Wall St. Rank hold RETA as of Q1 2022.

American Century Companies reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q1 2022 after selling out during the quarter.
American Century Companies sold 67,071 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q1 2022, an estimated $1.77M.
American Century Companies first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2018 and held it in 14 quarters.
American Century Companies's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $9.18M in Q2 2021.
149 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2022.

Based on American Century Companies's 13F filing for Q1 2022, filed 11 May 2022.